News Sentiment

ELTX sentiment intelligence

Elicio Therapeutics Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 48 Balanced news tone 53 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 3.48 Week of 10 Jul 2026
Weighted tone 48/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

83/100 classification confidence.

Company focus 45

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+8.1% over one week, -76.6% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Enterprise value to revenue forward of Elicio Therapeutics, Inc. – NASDAQ:ELTX

Market Reaction

Price moving ahead of tone

61/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 83/100 classification
One-week reaction 8.1% Price confirming higher
Trend fit Trend inactive -76.6% over four weeks
Fair value -53.9% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 11
Neutral 29
Negative 13

Relevance

Why the article matched

Direct first
Direct company coverage 45
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 7
Stock Titan 7
TradingView 6
GlobeNewswire 4
Investing.com 4
simplywall.st 4
The National Law Review 3
ACCESS Newswire 2

Event Lens

What the news is about

Classified themes
Market update 34
Earnings 11
Regulatory and legal 5
Balance sheet 2
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-53 of 53
Investing.com Direct company coverage

Elicio Therapeutics added to Russell 2000 and 3000 indexes

Elicio Therapeutics (NASDAQ:ELTX), a clinical-stage biotechnology company, has been added to the Russell 2000 and Russell 3000 indexes. This inclusion aims to boost the company's visibility among institutional investors, despite its stock trading at $4, a 50% decrease over the pa

Tone
Positive 71/100
Event
Market update
Published
29 Jun 2026 12:41
Source
Investing.com